The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Altered P2X7‐receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration
Abstract
The precise mechanism by which mutant huntingtin elicits its toxicity remains unknown. However synaptic alterations and increased susceptibility to neuronal death are known contributors to Huntington's disease (HD) symptomatology. While decreased metabolism has long been associated with HD, recent findings have surprisingly demonstrated reduced neuronal apoptosis in Caenorhabditis elegans and Drosophila models of HD by drugs that diminish ATP production. Interestingly, extracellular ATP has been recently reported to elicit neuronal death through stimulation of P2X7 receptors. These are ATP‐gated cation channels known to modulate neurotransmitter release from neuronal presynaptic terminals and to regulate cytokine production and release from microglia. We hypothesized that alteration in P2X7‐mediated calcium permeability may contribute to HD synaptic dysfunction and increased neuronal apoptosis. Using mouse and cellular models of HD, we demonstrate increased P2X7‐receptor level and altered P2X7‐mediated calcium permeability in somata and terminals of HD neurons. Furthermore, cultured neurons expressing mutant huntingtin showed increased susceptibility to apoptosis triggered by P2X7‐receptor stimulation. Finally, in vivo administration of the P2X7‐antagonist Brilliant Blue‐G (BBG) to HD mice prevented neuronal apoptosis and attenuated body weight loss and motor‐coordination deficits. These in vivo data strongly suggest that altered P2X7‐receptor level and function contribute to HD pathogenesis and highlight the therapeutic potential of P2X7 receptor antagonists.—Diaz‐Hernandez, M., Diez‐Zaera, M., Sanchez‐Nogueiro, J., Gomez‐Villafuertes, R., Canals, J.M., Alberch, J., Miras‐Portugal, M.T., Lucas, J.J. Altered P2X7‐receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J. 23, 1893–1906 (2009)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Molecular Physiology of P2X Receptors
North, R. A. (2002) · Physiological Reviews · doi:10.1152/physrev.00015.2002 · Cited by 2,919
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 3×
“The authors thank Drs. M. R. Fernández and C. Tomás for helpful discussion and comments; Dr. O. Howard for comments and style correction; and Drs. S. Finkbeiner and M. Arrasate (Gladstone Institute, San Francisco, CA, USA) for kindly providing plasmids expressing exon 1 htt fused to GFP with 17 or 72 Q repeats.”
BackgroundInfluentialThe Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739 · cited 1×
“The P2X7 receptor is an ATP-gated cation channel initially cloned from rat brain (20) and highly expressed in cells of hematopoietic lineage and in multiple cell types of the immune system (20).”
BackgroundThe Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G. P., & Davies, S. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110078997 · Cited by 430
Deuchars, S. A., Atkinson, L., Brooke, R. E., Musa, H., Milligan, C. J., Batten, T. F. C., Buckley, N. J., Parson, S. H., & Deuchars, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07143.2001 · Cited by 287 · cited 3×
“In view of these results, the previously reported axonal localization of P2X7 receptor (22, 24, 25) and the fact that cortex is the major source of axonal afference into the striatum, we reasoned that the striatal increase in P2X7 receptor level most likely occurs in axons of cortical neurons projecting to the striatu…”
BackgroundResultCellular localization of P2X7 receptor mRNA in the rat brain
Yu, Y., Ugawa, S., Ueda, T., Ishida, Y., Inoue, K., Kyaw Nyunt, A., Umemura, A., Mase, M., Yamada, K., & Shimada, S. (2008) · Brain Research · doi:10.1016/j.brainres.2007.11.064 · Cited by 132 · cited 7×
“Using quantitative RT-PCR, we then analyzed the level of P2X7 receptor mRNA in both mouse models with primers that recognize the exon 5-6 boundary of P2X7 mRNA.”
BackgroundResultInfluential
Cited by
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437
“Pretreatment with BBG has prevented NFκB activation and production of inflammatorymediators induced by gp120 in BV2 cells (Chen et al., 2016), suggesting a key role for P2X7 receptor in HIV-induced glial cells activation and brain damage.”
BackgroundResultInfluentialExtracellular ATP Is a Danger Signal Activating P2X7 Receptor in Lung Inflammation and Fibrosis
Riteau, N., Gasse, P., Fauconnier, L., Gombault, A., Couegnat, M., Fick, L., Kanellopoulos, J., Quesniaux, V. F. J., Marchand-Adam, S., Crestani, B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201003-0359oc · Cited by 397
“Our study proposes new targets for IPF, in particular the P2X7 receptor, for which inhibitors were shown to be efficient in animal models of neurological human diseases (48, 49).”
Purinergic signalling: From normal behaviour to pathological brain function
Burnstock, G., Krügel, U., Abbracchio, M. P., & Illes, P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.006 · Cited by 397
The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
Bartlett, R., Stokes, L., & Sluyter, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008003 · Cited by 393
P2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390
Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors
Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F. H., Cleveland, D. W., & Glass, C. K. (2014) · Nature Neuroscience · doi:10.1038/nn.3668 · Cited by 333
ATP as a multi-target danger signal in the brain
Rodrigues, R. J., Tomé, A. R., & Cunha, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00148 · Cited by 259
P2X7 Receptors: Channels, Pores and More
Volonte, C., Apolloni, S., D. Skaper, S., & Burnstock, G. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712803581137 · Cited by 254
Burnstock, G., & Knight, G. E. (2018) · Purinergic Signalling · doi:10.1007/s11302-017-9593-0 · Cited by 248
The microglial ATP‐gated ion channel P2X7 as a CNS drug target
Bhattacharya, A., & Biber, K. (2016) · Glia · doi:10.1002/glia.23001 · Cited by 221
New role of P2X7 receptor in an Alzheimer’s disease mouse model
Martin, E., Amar, M., Dalle, C., Youssef, I., Boucher, C., Le Duigou, C., Brückner, M., Prigent, A., Sazdovitch, V., Halle, A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0108-3 · Cited by 187
Neuronal P2X7 Receptors Revisited: Do They Really Exist?
Illes, P., Khan, T. M., & Rubini, P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3103-16.2017 · Cited by 179
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Significance of P2X7 Receptor Variants to Human Health and Disease
Sluyter, R., & Stokes, L. (2011) · Recent Patents on DNA & Gene Sequences · doi:10.2174/187221511794839219 · Cited by 147
Csölle, C., Andó, R. D., Kittel, Á., Gölöncsér, F., Baranyi, M., Soproni, K., Zelena, D., Haller, J., Németh, T., Mócsai, A., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001933 · Cited by 108
“The doses were chosen based on literature data (Diaz-Hernandez et al. 2009) and preliminary tests.”
MethodProphylactic systemic P2X7 receptor blockade prevents experimental colitis
Marques, C. C., Castelo-Branco, M. T., Pacheco, R. G., Buongusto, F., do Rosário, A., Schanaider, A., Coutinho-Silva, R., & de Souza, H. S. P. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.012 · Cited by 78
Blockage of P2X7 attenuates acute lung injury in mice by inhibiting NLRP3 inflammasome
Wang, S., Zhao, J., Wang, H., Liang, Y., Yang, N., & Huang, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.04.035 · Cited by 68
Wilkaniec, A., Gąssowska, M., Czapski, G. A., Cieślik, M., Sulkowski, G., & Adamczyk, A. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9567-2 · Cited by 61
“Deregulation of P2X7 receptor has previously been indicated to be common for diverse situations of brain damage, such as ischemia [61, 62], traumatic brain injury [63], spinal cord injury [64], epilepsy [65], Alzheimer’s disease [59, 66], Parkinson’s disease [67], prion disease [68], or Huntington’s disease [69].”
BackgroundPurinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
Ernest James Phillips, T., & Maguire, E. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.652593 · Cited by 33
Pang, F., Yang, Y., Huang, S., Yang, Z., Zhu, Z., Liao, D., Guo, X., Zhou, M., Li, Y., & Tang, C. (2023) · Brain Sciences · doi:10.3390/brainsci13030436 · Cited by 25
Bautista-Pérez, R., Pérez-Méndez, O., Cano-Martínez, A., Pacheco, U., Santamaría, J., Rodríguez-Sámano, F., Rodríguez-Iturbe, B., Navar, L. G., & Franco, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114041 · Cited by 25
Metadata
- Authors
- Díaz-Hernández, M., Díez-Zaera, M., Sánchez-Nogueiro, J., Gómez-Villafuertes, R., Canals, J. M., Alberch, J., Miras-Portugal, M. T., & Lucas, J. J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2009-01-26
- Volume
- 23
- Issue
- 6
- Pages
- 1893-1906
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2165709201
- Cited by
- 224
- References
- 8
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.